Home LiteratureArticle Details
PMID: 16106066 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

CD25+ CD4+ regulatory T-cells in cancer.

Immunologic research ·Vol. 32 ·No. 1-3 ·2005-00-00 ·Pages 155-68

Linehan DC, Goedegebuure PS

Abstract

Regulatory T-cells (Treg) protect the host from autoimmune disease by suppressing self-reactive immune cells. As such, Treg may also block antitumor immune responses. Recent observations by us and others showed that the prevalence of Treg is increased in cancer patients, particularly in the tumor environment. Our studies in a mouse pancreas cancer model suggest that the tumor actively promotes the accrual of Treg through several mechanisms involving activation of naturally occurring Treg as well as conversion of non-Treg into Treg. Our studies focus on further defining these mechanisms with the ultimate goal of designing strategies that block Treg-mediated suppression in cancer patients.

MeSH Terms
Animals Biomarkers, Tumor/immunology Breast Neoplasms/immunology CD4 Antigens/metabolism Cancer Vaccines/therapeutic use Carcinoma, Ductal, Breast/immunology Dendritic Cells/immunology,pathology Female Forkhead Transcription Factors/deficiency,genetics,immunology Humans Immune Tolerance Lymphocyte Depletion Mice Mice, Knockout Neoplasms/immunology,pathology,therapy Pancreatic Neoplasms/immunology,therapy Phenotype Receptors, Interleukin-2/metabolism T-Lymphocytes, Regulatory/immunology Transforming Growth Factor beta/metabolism
Chemicals
Biomarkers, Tumor CD4 Antigens Cancer Vaccines Forkhead Transcription Factors Foxp3 protein, mouse Receptors, Interleukin-2 Transforming Growth Factor beta
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Linehan David C
Department of Surgery and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA. [email protected]
Goedegebuure Peter S
References (58)
58 references, click to expand
  1. Sterility in neonatally thymectomized female mice: its nature and prevention by the injection of spleen cells.
    Biol Reprod. 1973 Apr;8(3):358-61 PMID: 4702798
  2. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.
    J Immunol. 2000 Jan 1;164(1):183-90 PMID: 10605010
  3. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.
    J Immunol. 2002 May 1;168(9):4272-6 PMID: 11970966
  4. Dendritic cells as a tool to induce anergic and regulatory T cells.
    Trends Immunol. 2001 Jul;22(7):394-400 PMID: 11429324
  5. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  6. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells.
    J Exp Med. 2004 Mar 15;199(6):879-84 PMID: 15007091
  7. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
    J Exp Med. 2003 Dec 15;198(12):1875-86 PMID: 14676299
  8. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood.
    J Immunol. 2001 Jun 15;166(12):7282-9 PMID: 11390478
  9. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
    J Immunol. 2003 Mar 15;170(6):2912-22 PMID: 12626542
  10. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors.
    Cancer Res. 1990 Apr 15;50(8):2228-33 PMID: 2317810
  11. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
    Nat Immunol. 2003 Apr;4(4):330-6 PMID: 12612578
  12. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.
    Nat Immunol. 2002 Feb;3(2):135-42 PMID: 11812990
  13. Neuropilin-1: a surface marker of regulatory T cells.
    Eur J Immunol. 2004 Mar;34(3):623-630 PMID: 14991591
  14. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.
    Immunology. 1988 Sep;65(1):87-92 PMID: 2972604
  15. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells.
    J Immunol. 2004 Aug 15;173(4):2428-34 PMID: 15294956
  16. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.
    J Exp Med. 1988 Dec 1;168(6):2193-206 PMID: 2974065
  17. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells.
    J Immunol. 2001 Aug 1;167(3):1137-40 PMID: 11466326
  18. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro.
    Eur J Immunol. 2001 Apr;31(4):1247-54 PMID: 11298351
  19. Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.
    Immunology. 1985 Jan;54(1):47-56 PMID: 3156088
  20. Does the immune system see tumors as foreign or self?
    Annu Rev Immunol. 2003;21:807-39 PMID: 12615893
  21. Control of autoimmunity by regulatory T cells.
    Adv Exp Med Biol. 2001;490:21-32 PMID: 11505971
  22. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.
    J Immunol. 2004 Jul 15;173(2):1444-53 PMID: 15240741
  23. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses.
    Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10902-6 PMID: 12947044
  24. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes.
    Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10878-83 PMID: 12949259
  25. Cancer immunotherapy: a treatment for the masses.
    Science. 2004 Jul 9;305(5681):200-5 PMID: 15247469
  26. Differential tumor surveillance by natural killer (NK) and NKT cells.
    J Exp Med. 2000 Feb 21;191(4):661-8 PMID: 10684858
  27. Differential expression of Smad7 transcripts identifies the CD4+CD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts.
    J Immunol. 2003 Aug 1;171(3):1140-7 PMID: 12874199
  28. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.
    Cancer Res. 2003 Aug 1;63(15):4516-20 PMID: 12907625
  29. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells.
    J Exp Med. 2003 Jul 21;198(2):235-47 PMID: 12874257
  30. Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma.
    Immunology. 1990 Sep;71(1):90-5 PMID: 2145216
  31. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
    Int Immunol. 1998 Dec;10(12):1969-80 PMID: 9885918
  32. An essential role for Scurfin in CD4+CD25+ T regulatory cells.
    Nat Immunol. 2003 Apr;4(4):337-42 PMID: 12612581
  33. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  34. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo.
    J Exp Med. 2003 Jul 21;198(2):249-58 PMID: 12874258
  35. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.
    J Exp Med. 1984 May 1;159(5):1295-311 PMID: 6232335
  36. Spontaneous development of autoimmune thyroiditis in neonatally thymectomized mice.
    Lab Invest. 1976 Jun;34(6):550-7 PMID: 947081
  37. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
    J Immunol. 1995 Aug 1;155(3):1151-64 PMID: 7636184
  38. Control of regulatory T cell development by the transcription factor Foxp3.
    Science. 2003 Feb 14;299(5609):1057-61 PMID: 12522256
  39. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  40. Development of effective immunotherapy for the treatment of patients with cancer.
    J Am Coll Surg. 2004 May;198(5):685-96 PMID: 15110801
  41. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy.
    Immunity. 2004 Jan;20(1):107-18 PMID: 14738769
  42. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo.
    Nat Immunol. 2002 Jan;3(1):33-41 PMID: 11740498
  43. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    J Exp Med. 2001 Sep 17;194(6):823-32 PMID: 11560997
  44. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
    Cancer Res. 1999 Jul 1;59(13):3128-33 PMID: 10397255
  45. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression.
    Cancer. 2003 Sep 1;98(5):1089-99 PMID: 12942579
  46. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    J Immunol. 2002 Sep 1;169(5):2756-61 PMID: 12193750
  47. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens.
    Nat Immunol. 2003 Jul;4(7):664-9 PMID: 12766766
  48. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals.
    Immunity. 2002 Feb;16(2):183-91 PMID: 11869680
  49. Increase of regulatory T cells in the peripheral blood of cancer patients.
    Clin Cancer Res. 2003 Feb;9(2):606-12 PMID: 12576425
  50. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
    Cancer Res. 1989 Apr 1;49(7):1649-54 PMID: 2522344
  51. IDDM in rats induced by thymectomy and irradiation.
    Diabetes. 1993 Apr;42(4):571-8 PMID: 8454108
  52. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
    Nature. 2001 Apr 26;410(6832):1107-11 PMID: 11323675
  53. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Cancer Res. 2001 Jun 15;61(12):4766-72 PMID: 11406550
  54. Involvement of the H+/K(+)-ATPase alpha subunit as a major antigenic protein in autoimmune gastritis induced by neonatal thymectomy in mice.
    Clin Exp Immunol. 1992 Jul;89(1):63-7 PMID: 1321013
  55. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells.
    Int J Cancer. 1993 Sep 9;55(2):338-43 PMID: 8103762
  56. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice.
    J Immunol. 2001 Jun 1;166(11):6972-81 PMID: 11359859
  57. Systemic and local immunosuppression in pancreatic cancer patients.
    Clin Cancer Res. 2001 Mar;7(3 Suppl):925s-932s PMID: 11300493
  58. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
    J Immunother. 2002 May-Jun;25(3):243-51 PMID: 12000866
Article Info
Journal
Immunologic research
Abbr.
Immunol Res
ISSN
0257-277X
DOI
10.1385/IR:32:1-3:155
Email
[email protected]
Published
2005-00-00
Pages
155-68
Language
English
Region
United States
NLM ID
8611087
Subset
IM
Grants
NCI NIH HHS · K08 CA87018 · United States
NCI NIH HHS · T32 CA09621 · United States
External Links
PubMed source DOI: 10.1385/IR:32:1-3:155 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2